{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:27:21Z","timestamp":1788582441609,"version":"build-2803163510"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00228-024-03658-w","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T13:02:37Z","timestamp":1709211757000},"page":"869-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The polymorphisms of candidate pharmacokinetic and pharmacodynamic genes and their pharmacogenetic impacts on the effectiveness of risperidone maintenance therapy among Saudi children with autism"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5020-6838","authenticated-orcid":false,"given":"Sireen Abdul Rahim","family":"Shilbayeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman Sharaf","family":"Adeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Shawqi","family":"Alhazmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haya","family":"Aljurayb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana Saad","family":"Altokhais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah","family":"Alhowaish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawlah Essa","family":"Aldilaijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar Mansour","family":"Alnakhli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"3658_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","volume":"32","author":"OD Howes","year":"2017","unstructured":"Howes OD, Rogdaki M, Findon JL et al (2017) Autism spectrum disorder: consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 32:3\u201329. https:\/\/doi.org\/10.1177\/0269881117741766","journal-title":"J Psychopharmacol"},{"key":"3658_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. American Psychiatric Association, Washington, DC"},{"key":"3658_CR3","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s10803-018-3521-1","volume":"48","author":"GN Soke","year":"2018","unstructured":"Soke GN, Maenner MJ, Christensen D, Kurzius-Spencer M, Schieve LA (2018) Prevalence of co-occurring medical and behavioral conditions\/symptoms among 4- and 8-year-old children with autism spectrum disorder in selected areas of the United States in 2010. J Autism Dev Disord 48:2663\u20132676. https:\/\/doi.org\/10.1007\/s10803-018-3521-1","journal-title":"J Autism Dev Disord"},{"key":"3658_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1192\/apt.bp.108.005538","volume":"16","author":"R Elvins","year":"2010","unstructured":"Elvins R, Green J (2010) Pharmacological management of core and comorbid symptoms in autism-spectrum disorder. Adv Psychiatr Treat 16:349\u2013360. https:\/\/doi.org\/10.1192\/apt.bp.108.005538","journal-title":"Adv Psychiatr Treat"},{"key":"3658_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.2217\/phe.10.45","volume":"4","author":"K Blankenship","year":"2010","unstructured":"Blankenship K, Erickson CA, Stigler KA, Posey DJ, McDougle CJ (2010) Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6\u201317 years. Pediatr Health 4:375\u2013381. https:\/\/doi.org\/10.2217\/phe.10.45","journal-title":"Pediatr Health"},{"key":"3658_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/jci32483","volume":"118","author":"DJ Posey","year":"2008","unstructured":"Posey DJ, Stigler KA, Erickson CA, McDougle CJ (2008) Antipsychotics in the treatment of autism. J Clin Investig 118:6\u201314. https:\/\/doi.org\/10.1172\/jci32483","journal-title":"J Clin Investig"},{"key":"3658_CR7","unstructured":"Janssen Pharmaceutica (2009) Risperidone [package insert]. July revision. Janssen Pharmaceutica, Titusville, NJ"},{"key":"3658_CR8","volume-title":"Aripiprazole [package insert]","author":"OPC Ltd","year":"2009","unstructured":"Ltd OPC (2009) Aripiprazole [package insert]. November revision. Otsuka Pharmaceutical Company Ltd., Tokyo, Japan"},{"key":"3658_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3389\/fphar.2020.00596","volume":"11","author":"I Yunusa","year":"2020","unstructured":"Yunusa I, El Helou ML (2020) The use of risperidone in behavioral and psychological symptoms of dementia: a review of pharmacology, clinical evidence, regulatory approvals, and off-label use. Front Pharmacol 11:596. https:\/\/doi.org\/10.3389\/fphar.2020.00596","journal-title":"Front Pharmacol"},{"key":"3658_CR10","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","volume":"162","author":"CJ McDougle","year":"2005","unstructured":"McDougle CJ, Scahill L, Aman MG et al (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142\u20131148. https:\/\/doi.org\/10.1176\/appi.ajp.162.6.1142","journal-title":"Am J Psychiatry"},{"key":"3658_CR11","doi-asserted-by":"publisher","first-page":"e634","DOI":"10.1542\/peds.2003-0264-f","volume":"114","author":"S Shea","year":"2004","unstructured":"Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F (2004) Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114:e634\u2013e641. https:\/\/doi.org\/10.1542\/peds.2003-0264-f","journal-title":"Pediatrics"},{"key":"3658_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1192\/bja.2022.61","volume":"29","author":"S Deb","year":"2022","unstructured":"Deb S, Roy M, Limbu B (2022) Pharmacological management of psychopathology in people with intellectual disabilities and\/or autism spectrum disorder. B J Psych Adv 29:1\u201312. https:\/\/doi.org\/10.1192\/bja.2022.61","journal-title":"B J Psych Adv"},{"key":"3658_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/phar.2271","volume":"39","author":"CL DeVane","year":"2019","unstructured":"DeVane CL, Charles JM, Abramson RK et al (2019) Pharmacotherapy of autism spectrum disorder: results from the randomized BAART clinical trial. Pharmacotherapy 39:626\u2013635. https:\/\/doi.org\/10.1002\/phar.2271","journal-title":"Pharmacotherapy"},{"key":"3658_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10578-013-0390-x","volume":"45","author":"A Ghanizadeh","year":"2014","unstructured":"Ghanizadeh A, Sahraeizadeh A, Berk M (2014) A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev 45:185\u2013192. https:\/\/doi.org\/10.1007\/s10578-013-0390-x","journal-title":"Child Psychiatry Hum Dev"},{"key":"3658_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40272-016-0183-3","volume":"18","author":"M Lamberti","year":"2016","unstructured":"Lamberti M, Siracusano R, Italiano D, Alosi N, Cucinotta F, Di Rosa G, German\u00f2 E, Spina E, Gagliano A (2016) Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD: a pilot, open-label, randomized controlled study. Pediatr Drugs 18:319\u2013329. https:\/\/doi.org\/10.1007\/s40272-016-0183-3","journal-title":"Pediatr Drugs"},{"key":"3658_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2313851","volume":"2022","author":"S Al-Huseini","year":"2022","unstructured":"Al-Huseini S, Al-Barhoumi A, Al-Balushi M, Al-Hosni A, Al-Mahrouqi T, Al-Mahrizi B, Jaju S, Mirza H (2022) Effectiveness and adverse effects of risperidone in children with autism spectrum disorder in a naturalistic clinical setting at a university hospital in Oman. Autism Res Treat 2022:1\u20137. https:\/\/doi.org\/10.1155\/2022\/2313851","journal-title":"Autism Res Treat"},{"key":"3658_CR17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/brainsci12050618","volume":"12","author":"HA Alsayouf","year":"2022","unstructured":"Alsayouf HA, Talo H, Biddappa ML (2022) Core signs and symptoms in children with autism spectrum disorder improved after starting risperidone and aripiprazole in combination with standard supportive therapies: a large, single-center, retrospective case series. Brain Sci 12:618. https:\/\/doi.org\/10.3390\/brainsci12050618","journal-title":"Brain Sci"},{"key":"3658_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/0253-7176.127254","volume":"36","author":"P Ghaeli","year":"2014","unstructured":"Ghaeli P, Nikvarz N, Alaghband-Rad J, Alimadadi A, Tehrani-Doost M (2014) Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study. Indian J Psychol Med 36:66\u201370. https:\/\/doi.org\/10.4103\/0253-7176.127254","journal-title":"Indian J Psychol Med"},{"key":"3658_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rasd.2020.101520","volume":"72","author":"ST Hesapcioglu","year":"2020","unstructured":"Hesapcioglu ST, Ceylan MF, Kasak M, Sen CP (2020) Olanzapine, risperidone, and aripiprazole use in children and adolescents with autism spectrum disorders. Res Autism Spectr Disord 72:101520. https:\/\/doi.org\/10.1016\/j.rasd.2020.101520","journal-title":"Res Autism Spectr Disord"},{"key":"3658_CR20","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2021.1003","volume":"7","author":"S Deb","year":"2021","unstructured":"Deb S, Roy M, Lee R, Majid M, Limbu B, Santambrogio J, Roy A, Bertelli MO (2021) Randomised controlled trials of antidepressant and anti-anxiety medications for people with autism spectrum disorder: systematic review and meta-analysis. BJPsych Open 7:e179. https:\/\/doi.org\/10.1192\/bjo.2021.1003","journal-title":"BJPsych Open"},{"key":"3658_CR21","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.3390\/ijms23126515","volume":"23","author":"A Lee","year":"2022","unstructured":"Lee A, Choo H, Jeon B (2022) Serotonin receptors as therapeutic targets for autism spectrum disorder treatment. Int J Mol Sci 23:6515. https:\/\/doi.org\/10.3390\/ijms23126515","journal-title":"Int J Mol Sci"},{"key":"3658_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13229-015-0055-7","volume":"6","author":"EL Burrows","year":"2015","unstructured":"Burrows EL, Laskaris L, Koyama L, Churilov L, Bornstein JC, Hill-Yardin EL, Hannan AJ (2015) A neuroligin-3 mutation implicated in autism causes abnormal aggression and increases repetitive behavior in mice. Mol Autism 6:62. https:\/\/doi.org\/10.1186\/s13229-015-0055-7","journal-title":"Mol Autism"},{"key":"3658_CR23","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1021\/acschemneuro.8b00159","volume":"9","author":"TC Chopko","year":"2018","unstructured":"Chopko TC, Lindsley CW (2018) Classics in chemical neuroscience: risperidone. ACS Chem Neurosci 9:1520\u20131529. https:\/\/doi.org\/10.1021\/acschemneuro.8b00159","journal-title":"ACS Chem Neurosci"},{"key":"3658_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.995439","volume":"13","author":"E Koch","year":"2022","unstructured":"Koch E, Demontis D (2022) Drug repurposing candidates to treat core symptoms in autism spectrum disorder. Front Pharmacol 13:995439. https:\/\/doi.org\/10.3389\/fphar.2022.995439","journal-title":"Front Pharmacol"},{"key":"3658_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/pl00005334","volume":"359","author":"J Fang","year":"1999","unstructured":"Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedeb Arch Pharmacol 359:147\u2013151. https:\/\/doi.org\/10.1007\/pl00005334","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"3658_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/cpt.910","volume":"103","author":"A Gaedigk","year":"2017","unstructured":"Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE (2017) The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther 103:399\u2013401. https:\/\/doi.org\/10.1002\/cpt.910","journal-title":"Clin Pharmacol Ther"},{"key":"3658_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.1651","volume":"107","author":"MV Relling","year":"2019","unstructured":"Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE (2019) The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther 107:171\u2013175. https:\/\/doi.org\/10.1002\/cpt.1651","journal-title":"Clin Pharmacol Ther"},{"key":"3658_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2019","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A (2019) Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci 13:116\u2013124. https:\/\/doi.org\/10.1111\/cts.12692","journal-title":"Clin Transl Sci"},{"key":"3658_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13034-018-0243-2","volume":"12","author":"T Dodsworth","year":"2018","unstructured":"Dodsworth T, Kim DD, Procyshyn RM, Ross CJ, Honer WG, Barr AM (2018) A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child Adolesc Psychiatry Ment Health 12:37. https:\/\/doi.org\/10.1186\/s13034-018-0243-2","journal-title":"Child Adolesc Psychiatry Ment Health"},{"key":"3658_CR30","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1089\/cap.2015.0094","volume":"25","author":"JA dos Santos","year":"2015","unstructured":"dos Santos JA, Henriques TB, de Mello MP, Neto APF, Paes LA, Torre OHD, Sewaybricker LE, Fontana TS, Celeri EHRV, J\u00fanior GG, Dalgalarrondo P (2015) Hyperprolactinemia in children and adolescents with use of risperidone: clinical and molecular genetics aspects. J Child Adolesc Psychopharmacol 25:738\u2013748. https:\/\/doi.org\/10.1089\/cap.2015.0094","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"3658_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/jcp.0000000000000474","volume":"36","author":"C Sukasem","year":"2016","unstructured":"Sukasem C, Hongkaew Y, Ngamsamut N, Puangpetch A, Vanwong N, Chamnanphon M, Chamkrachchangpada B, Sinrachatanant A, Limsila P (2016) Impact of pharmacogenetic markers of CYP2D6 and DRD2 on prolactin response in risperidone-treated Thai children and adolescents with autism spectrum disorders. J Clin Psychopharmacol 36:141\u2013146. https:\/\/doi.org\/10.1097\/jcp.0000000000000474","journal-title":"J Clin Psychopharmacol"},{"key":"3658_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/dbp.0000000000000883","volume":"42","author":"KM Rossow","year":"2021","unstructured":"Rossow KM, Oshikoya KA, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL (2021) Evidence for pharmacogenomic effects on risperidone outcomes in pediatrics. J Dev Behav Pediatr 42:205\u2013212. https:\/\/doi.org\/10.1097\/dbp.0000000000000883","journal-title":"J Dev Behav Pediatr"},{"key":"3658_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/tpj.2009.63","volume":"10","author":"CT Correia","year":"2009","unstructured":"Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, Oliveira GG, Vicente AM (2009) Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 10:418\u2013430. https:\/\/doi.org\/10.1038\/tpj.2009.63","journal-title":"Pharmacogenomics J"},{"key":"3658_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.4088\/jcp.v61n0810b","volume":"61","author":"C Guzey","year":"2000","unstructured":"Guzey C, Aamo T, Spigset O (2000) Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry 61:600\u2013601. https:\/\/doi.org\/10.4088\/jcp.v61n0810b","journal-title":"J Clin Psychiatry"},{"key":"3658_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/bcpt.12803","volume":"121","author":"N Nuntamool","year":"2017","unstructured":"Nuntamool N, Ngamsamut N, Vanwong N, Puangpetch A, Chamnanphon M, Hongkaew Y, Limsila P, Suthisisang C, Wilffert B, Sukasem C (2017) Pharmacogenomics and efficacy of risperidone long-term treatment in Thai autistic children and adolescents. Basic Clin Pharmacol Toxicol 121:316\u2013324. https:\/\/doi.org\/10.1111\/bcpt.12803","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3658_CR36","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fpsyt.2018.00002","volume":"9","author":"S Th\u00fcmmler","year":"2018","unstructured":"Th\u00fcmmler S, Dor E, David R, Leali G, Battista M, David A, Askenazy F, Verstuyft C (2018) Pharmacoresistant severe mental health disorders in children and adolescents: functional abnormalities of cytochrome P450 2D6. Front Psychiatry 9:2. https:\/\/doi.org\/10.3389\/fpsyt.2018.00002","journal-title":"Front Psychiatry"},{"key":"3658_CR37","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/dmcn.12470","volume":"56","author":"I Youngster","year":"2014","unstructured":"Youngster I, Zachor DA, Gabis LV, Bar-Chaim A, Benveniste-Levkovitz P, Britzi M, Soback S, Ziv-Baran T, Berkovitch M (2014) CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol 56:990\u2013994. https:\/\/doi.org\/10.1111\/dmcn.12470","journal-title":"Dev Med Child Neurol"},{"key":"3658_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.736626","volume":"12","author":"M Hiratsuka","year":"2021","unstructured":"Hiratsuka M, Zhou Y, Lauschke VM (2021) Editorial: population pharmacogenomics (PGx): from variant identification to clinical implementation. Front Genet 12:736626. https:\/\/doi.org\/10.3389\/fgene.2021.736626","journal-title":"Front Genet"},{"key":"3658_CR39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1089\/omi.2018.0114","volume":"22","author":"M-EG Naranjo","year":"2018","unstructured":"Naranjo M-EG, Rodrigues-Soares F, Pe\u00f1as-Lled\u00f3 EM et al (2018) Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 ibero- and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics. OMICS 22:575\u2013588. https:\/\/doi.org\/10.1089\/omi.2018.0114","journal-title":"OMICS"},{"key":"3658_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41397-022-00288-2","volume":"22","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Lauschke VM (2022) The genetic landscape of major drug metabolizing cytochrome P450 genes\u2014an updated analysis of population-scale sequencing data. Pharmacogenomics J 22:284\u2013293. https:\/\/doi.org\/10.1038\/s41397-022-00288-2","journal-title":"Pharmacogenomics J"},{"key":"3658_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2217\/17410541.4.3.271","volume":"4","author":"C Correia","year":"2007","unstructured":"Correia C, Vicente AM (2007) Pharmacogenetics of risperidone response and induced side effects. Pers Med 4:271\u2013293. https:\/\/doi.org\/10.2217\/17410541.4.3.271","journal-title":"Pers Med"},{"key":"3658_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.31887\/dcns.2016.18.3\/ceap","volume":"18","author":"CB Eap","year":"2022","unstructured":"Eap CB (2022) Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs. Dialogues Clin Neurosci 18:313\u2013322. https:\/\/doi.org\/10.31887\/dcns.2016.18.3\/ceap","journal-title":"Dialogues Clin Neurosci"},{"key":"3658_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.31887\/dcns.2016.18.3\/jbishop","volume":"18","author":"S Eum","year":"2022","unstructured":"Eum S, Lee AM, Bishop JR (2022) Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations. Dialogues Clin Neurosci 18:323\u2013337. https:\/\/doi.org\/10.31887\/dcns.2016.18.3\/jbishop","journal-title":"Dialogues Clin Neurosci"},{"key":"3658_CR44","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/genes10060416","volume":"10","author":"CH van der Wouden","year":"2019","unstructured":"van der Wouden CH, Bank PCD, \u00d6zokcu K, Swen JJ, Guchelaar H-J (2019) Pharmacist-initiated pre-emptive pharmacogenetic panel testing with clinical decision support in primary care: record of PGx results and real-world impact. Genes 10:416. https:\/\/doi.org\/10.3390\/genes10060416","journal-title":"Genes"},{"key":"3658_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN (2019) The REDCap consortium: building an international community of software platform partners. J Biomed Inform 95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","journal-title":"J Biomed Inform"},{"key":"3658_CR46","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1037\/t10453-000","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89:485\u2013491. https:\/\/doi.org\/10.1037\/t10453-000","journal-title":"Am J Ment Defic"},{"key":"3658_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10803-006-0234-7","volume":"37","author":"GJ Pandina","year":"2007","unstructured":"Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F (2007) Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 37:367\u2013373. https:\/\/doi.org\/10.1007\/s10803-006-0234-7","journal-title":"J Autism Dev Disord"},{"key":"3658_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1797","volume":"28","author":"E de Beurs","year":"2019","unstructured":"de Beurs E, Carlier IVE, Hemert AM (2019) Approaches to denote treatment outcome: clinical significance and clinical global impression compared. Int J Methods Psychiatr Res 28:e1797. https:\/\/doi.org\/10.1002\/mpr.1797","journal-title":"Int J Methods Psychiatr Res"},{"key":"3658_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.542342","volume":"12","author":"PF Salles","year":"2021","unstructured":"Salles PF, Perce-da-Silva DS, Rossi AD, Raposo LR, Ramirez ADR, Bastos OMP, Pratt-Riccio LR, Cassiano GC, Baptista ARS, Cardoso CC, Banic DM, Machado RLD (2021) CYP2D6 allele frequency in five malaria vivax endemic areas from Brazilian Amazon region. Front Pharmacol 12:542342. https:\/\/doi.org\/10.3389\/fphar.2021.542342","journal-title":"Front Pharmacol"},{"key":"3658_CR50","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.2350","volume":"110","author":"M Whirl-Carrillo","year":"2021","unstructured":"Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, Klein TE (2021) An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 110:563\u2013572. https:\/\/doi.org\/10.1002\/cpt.2350","journal-title":"Clin Pharmacol Ther"},{"key":"3658_CR51","unstructured":"Scientifuic. ThermoFisher Axiom pharmacofocus. https:\/\/www.thermofisher.com\/order\/catalog\/product\/952425. Accessed 3 Jul 2022"},{"key":"3658_CR52","first-page":"509","volume":"30","author":"C Bruckner","year":"2022","unstructured":"Bruckner C, Shah M, Black D, Marjanovic M (2022) Preemptive targeted pharmacogenomic testing with axiom PharmacoFocus array. Eur J Hum Genet 30:509","journal-title":"Eur J Hum Genet"},{"key":"3658_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cpt.1643","volume":"107","author":"C Nofziger","year":"2020","unstructured":"Nofziger C, Turner AJ, Sangkuhl K et al (2020) PharmVar GeneFocus: CYP2D6. Clin Pharmacol Ther 107:154\u2013170. https:\/\/doi.org\/10.1002\/cpt.1643","journal-title":"Clin Pharmacol Ther"},{"key":"3658_CR54","unstructured":"FDA (2012) Risperdal\u00ae prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020272s065,020588s053,021444s041lbl.pdf. Accessed 26 Jun 2022"},{"key":"3658_CR55","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","volume":"43","author":"JM Kent","year":"2013","unstructured":"Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, Singh J, Hough D (2013) Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord 43:1773\u20131783. https:\/\/doi.org\/10.1007\/s10803-012-1723-5","journal-title":"J Autism Dev Disord"},{"key":"3658_CR56","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eurpsy.2015.11.004","volume":"32","author":"SZ Levine","year":"2016","unstructured":"Levine SZ, Kodesh A, Goldberg Y, Reichenberg A, Furukawa TA, Kolevzon A, Leucht S (2016) Initial severity and efficacy of risperidone in autism: results from the RUPP trial. Eur Psychiatry 32:16\u201320. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.11.004","journal-title":"Eur Psychiatry"},{"key":"3658_CR57","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","unstructured":"Research Units on Pediatric Psychopharmacology Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361\u20131369. https:\/\/doi.org\/10.1176\/appi.ajp.162.7.1361. Risperdal (risperidone) tablets label (fda.gov)","journal-title":"Am J Psychiatry"},{"key":"3658_CR58","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","volume":"44","author":"PW Troost","year":"2005","unstructured":"Troost PW, Lahuis BE, Steenhuis M-P, Ketelaars CEJ, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ (2005) Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44:1137\u20131144. https:\/\/doi.org\/10.1097\/01.chi.0000177055.11229.76","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"3658_CR59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.20517\/jtgg.2021.25","volume":"5","author":"A Hervas","year":"2021","unstructured":"Hervas A, Serra-Llovich A, Rueda I, Targa I, Guijarro S, Bigorra A, Cancino M, Bote V, C\u00e1rcel M, Amasi-Hartoonian N, Hernandez M, Arranz MJ (2021) Pharmacogenetic influences on the response to pharmacological treatment in autism spectrum disorders. J Transl Genet Genom 5:278\u2013287. https:\/\/doi.org\/10.20517\/jtgg.2021.25","journal-title":"J Transl Genet Genom"},{"key":"3658_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/ftd.0b013e3182126d83","volume":"33","author":"K Seto","year":"2011","unstructured":"Seto K, Dumontet J, Ensom MHH (2011) Risperidone in schizophrenia: is there a role for therapeutic drug monitoring? Ther Drug Monit 33:275\u2013283. https:\/\/doi.org\/10.1097\/ftd.0b013e3182126d83","journal-title":"Ther Drug Monit"},{"key":"3658_CR61","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00702-022-02485-6","volume":"129","author":"R Taurines","year":"2022","unstructured":"Taurines R, Fekete S, Preuss-Wiedenhoff A, Warnke A, Wewetzer C, Plener P, Burger R, Gerlach M, Romanos M, Egberts KM (2022) Therapeutic drug monitoring in children and adolescents with schizophrenia and other psychotic disorders using risperidone. J Neural Transm 129:689\u2013701. https:\/\/doi.org\/10.1007\/s00702-022-02485-6","journal-title":"J Neural Transm"},{"key":"3658_CR62","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/biomedicines8040094","volume":"8","author":"M Saiz-Rodr\u00edguez","year":"2020","unstructured":"Saiz-Rodr\u00edguez M, Almenara S, Navares-G\u00f3mez M, Ochoa D, Rom\u00e1n M, Zubiaur P, Koller D, Santos M, Mej\u00eda G, Borobia AM, Rodr\u00edguez-Antona C, Abad-Santos F (2020) Effect of the most relevant CYP3A4 and CYP3A5 polymorphisms on the pharmacokinetic parameters of 10 CYP3A substrates. Biomedicines 8:94. https:\/\/doi.org\/10.3390\/biomedicines8040094","journal-title":"Biomedicines"},{"key":"3658_CR63","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1073\/pnas.0906080106","volume":"107","author":"B Crespi","year":"2010","unstructured":"Crespi B, Stead P, Elliot M (2010) Comparative genomics of autism and schizophrenia. Proc Natl Acad Sci U S A 107:1736\u20131741. https:\/\/doi.org\/10.1073\/pnas.0906080106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3658_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/tpj.2010.73","volume":"11","author":"N Fleeman","year":"2010","unstructured":"Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, Pirmohamed M, Walley T (2010) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 11:1\u201314. https:\/\/doi.org\/10.1038\/tpj.2010.73","journal-title":"Pharmacogenomics J"},{"key":"3658_CR65","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1097\/gim.0b013e3181863239","volume":"10","author":"I Grossman","year":"2008","unstructured":"Grossman I, Sullivan PF, Walley N, Liu Y, Dawson JR, Gumbs C, Gaedigk A, Leeder JS, McEvoy JP, Weale ME, Goldstein DB (2008) Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med 10:720\u2013729. https:\/\/doi.org\/10.1097\/gim.0b013e3181863239","journal-title":"Genet Med"},{"key":"3658_CR66","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.schres.2015.08.002","volume":"168","author":"MT van de Bilt","year":"2015","unstructured":"van de Bilt MT, Prado CM, Ojopi EPB, de Sousa RT, Loch AA, Zanetti MV, Talib LL, Gattaz WF (2015) Corrigendum to cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. Schizophr Res 168:587\u2013588. https:\/\/doi.org\/10.1016\/j.schres.2015.08.002","journal-title":"Schizophr Res"},{"key":"3658_CR67","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/s41390-019-0305-z","volume":"85","author":"KA Oshikoya","year":"2019","unstructured":"Oshikoya KA, Neely KM, Carroll RJ, Aka IT, Maxwell-Horn AC, Roden DM, Van Driest SL (2019) CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatr Res 85:602\u2013606. https:\/\/doi.org\/10.1038\/s41390-019-0305-z","journal-title":"Pediatr Res"},{"key":"3658_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0511-9","volume":"9","author":"MJ Arranz","year":"2019","unstructured":"Arranz MJ, Gonzalez-Rodriguez A, Perez-Blanco J, Penad\u00e9s R, Gutierrez B, Iba\u00f1ez L, Arias B, Brunet M, Cervilla J, Salazar J, Catalan R (2019) A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Transl Psychiatry 9:1\u20138. https:\/\/doi.org\/10.1038\/s41398-019-0511-9","journal-title":"Transl Psychiatry"},{"key":"3658_CR69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40780-018-0126-y","volume":"4","author":"T Ito","year":"2018","unstructured":"Ito T, Yamamoto K, Ohsawa F, Otsuka I, Hishimoto A, Sora I, Hirai M, Yano I (2018) Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study. J Pharm Health Care Sci 4:28. https:\/\/doi.org\/10.1186\/s40780-018-0126-y","journal-title":"J Pharm Health Care Sci"},{"key":"3658_CR70","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41397-019-0142-9","volume":"20","author":"MS Calafato","year":"2020","unstructured":"Calafato MS, Austin-Zimmerman I, Thygesen JH, Sairam M, Metastasio A, Marston L, Abad-Santos F, Bhat A, Harju-Sepp\u00e4nen J, Irizar H, Zartaloudi E, Bramon E (2020) The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis. Pharmacogenomics J 20:629\u2013637. https:\/\/doi.org\/10.1038\/s41397-019-0142-9","journal-title":"Pharmacogenomics J"},{"key":"3658_CR71","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.3389\/fpsyg.2021.768748","volume":"12","author":"Y Wannasuphoprasit","year":"2022","unstructured":"Wannasuphoprasit Y, Andersen SE, Arranz MJ et al (2022) CYP2D6 genetic variation and antipsychotic-induced weight gain: a systematic review and meta-analysis. Front Psychol 12:6218. https:\/\/doi.org\/10.3389\/fpsyg.2021.768748","journal-title":"Front Psychol"},{"key":"3658_CR72","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/s0163-7258(01)00139-5","volume":"90","author":"JN Joyce","year":"2001","unstructured":"Joyce JN (2001) Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90:231\u2013259. https:\/\/doi.org\/10.1016\/s0163-7258(01)00139-5","journal-title":"Pharmacol Ther"},{"key":"3658_CR73","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.euroneuro.2014.08.011","volume":"25","author":"WG Staal","year":"2015","unstructured":"Staal WG (2015) Autism, DRD3 and repetitive and stereotyped behavior, an overview of the current knowledge. Eur Neuropsychopharmacol 25:1421\u20131426. https:\/\/doi.org\/10.1016\/j.euroneuro.2014.08.011","journal-title":"Eur Neuropsychopharmacol"},{"key":"3658_CR74","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.3389\/fpsyt.2021.787097","volume":"12","author":"V Mandic-Maravic","year":"2022","unstructured":"Mandic-Maravic V, Grujicic R, Milutinovic L, Munjiza-Jovanovic A, Pejovic-Milovancevic M (2022) Dopamine in autism spectrum disorders\u2014focus on D2\/D3 partial agonists and their possible use in treatment. Front Psychiatry 12:2543. https:\/\/doi.org\/10.3389\/fpsyt.2021.787097","journal-title":"Front Psychiatry"},{"key":"3658_CR75","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1176\/appi.ajp.2009.09040598","volume":"167","author":"J-P Zhang","year":"2010","unstructured":"Zhang J-P, Lencz T, Malhotra AK (2010) D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry 167:763\u2013772. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09040598","journal-title":"Am J Psychiatry"},{"key":"3658_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106963","volume":"88","author":"Z-Y Cheng","year":"2020","unstructured":"Cheng Z-Y, Xia Q-P, Hu Y-H, Wang C, He L (2020) Dopamine D1 receptor agonist A-68930 ameliorates A\u03b21-42-induced cognitive impairment and neuroinflammation in mice. Int Immunopharmacol 88:106963. https:\/\/doi.org\/10.1016\/j.intimp.2020.106963","journal-title":"Int Immunopharmacol"},{"key":"3658_CR77","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/bne0000512","volume":"136","author":"MA Weber","year":"2022","unstructured":"Weber MA, Conlon MM, Stutt HR, Wendt L, Ten Eyck P, Narayanan NS (2022) Quantifying the inverted U: a meta-analysis of prefrontal dopamine, D1 receptors, and working memory. Behav Neurosci 136:207\u2013218. https:\/\/doi.org\/10.1037\/bne0000512","journal-title":"Behav Neurosci"},{"key":"3658_CR78","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s44159-022-00146-9","volume":"2","author":"D-W Zhang","year":"2023","unstructured":"Zhang D-W, Sauce B (2023) Efficiency and capacity mechanisms can coexist in cognitive training. Nat Rev Psychol 2:127. https:\/\/doi.org\/10.1038\/s44159-022-00146-9","journal-title":"Nat Rev Psychol"},{"key":"3658_CR79","doi-asserted-by":"publisher","first-page":"5658","DOI":"10.1007\/s12035-017-0770-5","volume":"55","author":"Y Lee","year":"2018","unstructured":"Lee Y, Kim H, Kim J-E, Park J-Y, Choi J, Lee J-E, Lee E-H, Han P-L (2018) Excessive D1 dopamine receptor activation in the dorsal striatum promotes autistic-like behaviors. Mol Neurobiol 55:5658\u20135671. https:\/\/doi.org\/10.1007\/s12035-017-0770-5","journal-title":"Mol Neurobiol"},{"key":"3658_CR80","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/jmisr.jmisr_8_18","volume":"1","author":"AA Azzam","year":"2018","unstructured":"Azzam AA, Bahgat DR, Shahin RH, Nasralla RA (2018) Association study between polymorphisms of dopamine transporter gene (SLC6A3), dopamine D1 receptor gene (DRD1), and autism. J Med Sci Res 1:59. https:\/\/doi.org\/10.4103\/jmisr.jmisr_8_18","journal-title":"J Med Sci Res"},{"key":"3658_CR81","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/ypg.0000000000000316","volume":"32","author":"I Mpoulimari","year":"2022","unstructured":"Mpoulimari I, Zintzaras E (2022) Synthesis of genetic association studies on autism spectrum disorders using a genetic model-free approach. Psychiatr Genet 32:91\u2013104. https:\/\/doi.org\/10.1097\/ypg.0000000000000316","journal-title":"Psychiatr Genet"},{"key":"3658_CR82","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/15622975.2010.543431","volume":"13","author":"CC Zai","year":"2012","unstructured":"Zai CC, Ehtesham S, Choi E, Nowrouzi B, de Luca V, Stankovich L, Davidge K, Freeman N, King N, Kennedy JL, Beitchman JH (2012) Dopaminergic system genes in childhood aggression: possible role for DRD2. World J Biol Psychiatry 13:65\u201374. https:\/\/doi.org\/10.3109\/15622975.2010.543431","journal-title":"World J Biol Psychiatry"},{"key":"3658_CR83","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/bcpt.13111","volume":"124","author":"L Ma","year":"2019","unstructured":"Ma L, Zhang X, Xiang Q, Zhou S, Zhao N, Xie Q, Zhao X, Zhou Y, Cui Y (2019) Association between dopamine receptor gene polymorphisms and effects of risperidone treatment: a systematic review and meta-analysis. Basic Clin Pharmacol Toxicol 124:94\u2013104. https:\/\/doi.org\/10.1111\/bcpt.13111","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3658_CR84","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/jhg.2012.157","volume":"58","author":"Y-L Chien","year":"2013","unstructured":"Chien Y-L, Hwu H-G, Fann CSJ, Chang C-C, Tsuang M-T, Liu C-M (2013) DRD2 haplotype associated with negative symptoms and sustained attention deficits in Han Chinese with schizophrenia in Taiwan. J Hum Genet 58:229\u2013232. https:\/\/doi.org\/10.1038\/jhg.2012.157","journal-title":"J Hum Genet"},{"key":"3658_CR85","doi-asserted-by":"publisher","first-page":"869","DOI":"10.2217\/pgs.14.50","volume":"15","author":"MD Brennan","year":"2014","unstructured":"Brennan MD (2014) Pharmacogenetics of second-generation antipsychotics. Pharmacogenomics 15:869\u2013884. https:\/\/doi.org\/10.2217\/pgs.14.50","journal-title":"Pharmacogenomics"},{"key":"3658_CR86","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2217\/14622416.9.10.1437","volume":"9","author":"M Ikeda","year":"2008","unstructured":"Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, O\u2019Donovan MC, Nakamura J, Ozaki N, Iwata N (2008) Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 9:1437\u20131443. https:\/\/doi.org\/10.2217\/14622416.9.10.1437","journal-title":"Pharmacogenomics"},{"key":"3658_CR87","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/jcp.0b013e31822cfff2","volume":"31","author":"R L\u00f3pez-Rodr\u00edguez","year":"2011","unstructured":"L\u00f3pez-Rodr\u00edguez R, Rom\u00e1n M, Novalbos J, Pelegrina ML, Ochoa D, Abad-Santos F (2011) DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. J Clin Psychopharmacol 31:555\u2013562. https:\/\/doi.org\/10.1097\/jcp.0b013e31822cfff2","journal-title":"J Clin Psychopharmacol"},{"key":"3658_CR88","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/schbul\/sbv116","volume":"41","author":"J-P Zhang","year":"2015","unstructured":"Zhang J-P, Robinson DG, Gallego JA, John M, Yu J, Addington J, Tohen M, Kane JM, Malhotra AK, Lencz T (2015) Association of a schizophrenia risk variant at the drd2 locus with antipsychotic treatment response in first-episode psychosis. Schizophr Bull 41:1248\u20131255. https:\/\/doi.org\/10.1093\/schbul\/sbv116","journal-title":"Schizophr Bull"},{"key":"3658_CR89","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","volume":"18","author":"Kwon JS, Kim E, Kang D-H, Choi JS, Yu K-S, Jang I-J, Shin S-G, APLUS Study Group","year":"2008","unstructured":"Kwon JS, Kim E, Kang D-H, Choi JS, Yu K-S, Jang I-J, Shin S-G, APLUS Study Group (2008) Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. Eur Neuropsychopharmacol 18:897\u2013907. https:\/\/doi.org\/10.1016\/j.euroneuro.2008.07.010","journal-title":"Eur Neuropsychopharmacol"},{"key":"3658_CR90","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jpsychires.2008.09.005","volume":"43","author":"Y-C Shen","year":"2009","unstructured":"Shen Y-C, Chen S-F, Chen C-H, Lin CCH, Chen S-J, Chen Y-J, Luu S-U (2009) Effects of DRD2\/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. J Psychiatr Res 43:600\u2013606. https:\/\/doi.org\/10.1016\/j.jpsychires.2008.09.005","journal-title":"J Psychiatr Res"},{"key":"3658_CR91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2174\/187152706784111551","volume":"5","author":"L Leriche","year":"2006","unstructured":"Leriche L, Bezard E, Gross C, Guillin O, Foll B, Diaz J, Sokoloff P (2006) The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets (Former Curr Drug Targets CNS Neurol Disord) 5:25\u201343. https:\/\/doi.org\/10.2174\/187152706784111551","journal-title":"CNS Neurol Disord Drug Targets (Former Curr Drug Targets CNS Neurol Disord)"},{"key":"3658_CR92","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3389\/fnins.2016.00451","volume":"10","author":"S Maramai","year":"2016","unstructured":"Maramai S, Gemma S, Brogi S, Campiani G, Butini S, Stark H, Brindisi M (2016) Dopamine D3 receptor antagonists as potential therapeutics for the treatment of neurological diseases. Front Neurosci 10:451. https:\/\/doi.org\/10.3389\/fnins.2016.00451","journal-title":"Front Neurosci"},{"key":"3658_CR93","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/npp.2011.254","volume":"37","author":"DJG Watson","year":"2012","unstructured":"Watson DJG, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KCF (2012) Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology 37:770\u2013786. https:\/\/doi.org\/10.1038\/npp.2011.254","journal-title":"Neuropsychopharmacology"},{"key":"3658_CR94","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s10803-011-1312-z","volume":"42","author":"WG Staal","year":"2012","unstructured":"Staal WG, de Krom M, de Jonge MV (2012) Brief report: the dopamine-3-receptor gene (DRD3) is associated with specific repetitive behavior in autism spectrum disorder (ASD). J Autism Dev Disord 42:885\u2013888. https:\/\/doi.org\/10.1007\/s10803-011-1312-z","journal-title":"J Autism Dev Disord"},{"key":"3658_CR95","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1192\/bjp.bp.114.148973","volume":"206","author":"WG Staal","year":"2015","unstructured":"Staal WG, Langen M, van Dijk S, Mensen VT, Durston S (2015) DRD3 gene and striatum in autism spectrum disorder. Br J Psychiatry 206:431\u2013432. https:\/\/doi.org\/10.1192\/bjp.bp.114.148973","journal-title":"Br J Psychiatry"},{"key":"3658_CR96","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/tpj.2009.26","volume":"9","author":"P Gass\u00f3","year":"2009","unstructured":"Gass\u00f3 P, Mas S, Bernardo M, \u00c1lvarez S, Parellada E, Lafuente A (2009) A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. Pharmacogenomics J 9:404\u2013410. https:\/\/doi.org\/10.1038\/tpj.2009.26","journal-title":"Pharmacogenomics J"},{"key":"3658_CR97","doi-asserted-by":"publisher","first-page":"445","DOI":"10.18433\/j3h63t","volume":"20","author":"N Firouzabadi","year":"2017","unstructured":"Firouzabadi N, Nazariat A, Zomorrodian K (2017) DRD3 Ser9Gly polymorphism and its influence on risperidone response in autistic children. J Pharm Pharm Sci 20:445\u2013452. https:\/\/doi.org\/10.18433\/j3h63t","journal-title":"J Pharm Pharm Sci"},{"key":"3658_CR98","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/tpj.2009.65","volume":"10","author":"R Hwang","year":"2010","unstructured":"Hwang R, Zai C, Tiwari A, M\u00fcller DJ, Arranz MJ, Morris AG, McKenna PJ, Munro J, Potkin SG, Lieberman JA, Meltzer HY, Kennedy JL (2010) Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. Pharmacogenomics J 10:200\u2013218. https:\/\/doi.org\/10.1038\/tpj.2009.65","journal-title":"Pharmacogenomics J"},{"key":"3658_CR99","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.schres.2006.01.010","volume":"83","author":"PR Bakker","year":"2006","unstructured":"Bakker PR, van Harten PN, van Os J (2006) Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83:185\u2013192. https:\/\/doi.org\/10.1016\/j.schres.2006.01.010","journal-title":"Schizophr Res"},{"key":"3658_CR100","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/wnn.0000000000000028","volume":"27","author":"KD Gadow","year":"2014","unstructured":"Gadow KD, Smith RM, Pinsonneault JK (2014) Serotonin 2A receptor gene (HTR2A) regulatory variants: possible association with severity of depression symptoms in children with autism spectrum disorder. Cogn Behav Neurol 27:107\u2013116. https:\/\/doi.org\/10.1097\/wnn.0000000000000028","journal-title":"Cogn Behav Neurol"},{"key":"3658_CR101","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.4172\/neuropsychiatry.1000547","volume":"9","author":"A Cieslinska","year":"2019","unstructured":"Cieslinska A, Fiedorowicz E, Jarmolowska B, Kordulewska N, Kostyra E, Moszynska M, Savelkoul HFJ (2019) Polymorphisms rs6313 and rs6314 in serotonin receptor gene (HTR2A) and serotonin concentration in autistic children. Neuropsychiatry 9:2021\u20132028. https:\/\/doi.org\/10.4172\/neuropsychiatry.1000547","journal-title":"Neuropsychiatry"},{"key":"3658_CR102","doi-asserted-by":"publisher","first-page":"1606555","DOI":"10.1080\/23312025.2019.1606555","volume":"5","author":"NA Elhawary","year":"2019","unstructured":"Elhawary NA, Tayeb MT, Sindi IA, Qutub N, Rashad M, Mufti A, Arab AH, Khogeer A, Elhawary EN, Dannoun A, Bogari N (2019) Genetic biomarkers predict susceptibility to autism spectrum disorder through interactive models of inheritance in a Saudi community. Cogent Biol 5:1606555. https:\/\/doi.org\/10.1080\/23312025.2019.1606555","journal-title":"Cogent Biol"},{"key":"3658_CR103","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11011-021-00699-3","volume":"36","author":"J Liu","year":"2021","unstructured":"Liu J, Fu H, Kong J, Yu H, Zhang Z (2021) Association between autism spectrum disorder and polymorphisms in genes encoding serotine and dopamine receptors. Metab Brain Dis 36:865\u2013870. https:\/\/doi.org\/10.1007\/s11011-021-00699-3","journal-title":"Metab Brain Dis"},{"key":"3658_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1471-244x-8-40","volume":"8","author":"D Benmessaoud","year":"2008","unstructured":"Benmessaoud D, Hamdani N, Boni C, Ramoz N, Hamon M, Kacha F, Gorwood P (2008) Excess of transmission of the G allele of the -1438A\/G polymorphism of the 5-HT2Areceptor gene in patients with schizophrenia responsive to antipsychotics. BMC Psychiatry 8:40. https:\/\/doi.org\/10.1186\/1471-244x-8-40","journal-title":"BMC Psychiatry"},{"key":"3658_CR105","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1176\/appi.ajp.159.9.1593","volume":"159","author":"H-Y Lane","year":"2002","unstructured":"Lane H-Y, Chang Y-C, Chiu C-C, Chen M-L, Hsieh M-H, Chang W-H (2002) Association of risperidone treatment response with a polymorphism in the 5-HT2A receptor gene. Am J Psychiatry 159:1593\u20131595. https:\/\/doi.org\/10.1176\/appi.ajp.159.9.1593","journal-title":"Am J Psychiatry"},{"key":"3658_CR106","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ddr.21686","volume":"81","author":"E Maffioletti","year":"2020","unstructured":"Maffioletti E, Valsecchi P, Minelli A, Magri C, Bonvicini C, Barlati S, Sacchetti E, Vita A, Gennarelli M (2020) Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. Drug Dev Res 81:754\u2013761. https:\/\/doi.org\/10.1002\/ddr.21686","journal-title":"Drug Dev Res"},{"key":"3658_CR107","first-page":"5","volume":"55","author":"JE Leysen","year":"1994","unstructured":"Leysen JE, Janssen PM, Megens AA, Schotte A (1994) Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry 55:5\u201312","journal-title":"J Clin Psychiatry"},{"key":"3658_CR108","volume":"12","author":"E Challet","year":"2022","unstructured":"Challet E, Jeong JK, Mounien L (2022) Central 5-HTR2C in the control of metabolic homeostasis. Cent Regul Metab 12:694204","journal-title":"Cent Regul Metab"},{"key":"3658_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.711940","volume":"12","author":"P Soria-Chacartegui","year":"2021","unstructured":"Soria-Chacartegui P, Villapalos-Garc\u00eda G, Zubiaur P, Abad-Santos F, Koller D (2021) Genetic polymorphisms associated with the pharmacokinetics, pharmacodynamics and adverse effects of olanzapine, aripiprazole and risperidone. Front Pharmacol 12:711940. https:\/\/doi.org\/10.3389\/fphar.2021.711940","journal-title":"Front Pharmacol"},{"key":"3658_CR110","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jamapsychiatry.2013.1378","volume":"70","author":"G Blasi","year":"2013","unstructured":"Blasi G, De Virgilio C, Papazacharias A et al (2013) Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiat 70:921\u2013930. https:\/\/doi.org\/10.1001\/jamapsychiatry.2013.1378","journal-title":"JAMA Psychiat"},{"key":"3658_CR111","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/jnr.10173","volume":"67","author":"OO Polesskaya","year":"2002","unstructured":"Polesskaya OO, Sokolov BP (2002) Differential expression of the\u202f?C? and\u202f?T? alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67:812\u2013822. https:\/\/doi.org\/10.1002\/jnr.10173","journal-title":"J Neurosci Res"},{"key":"3658_CR112","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1373\/49.4.542","volume":"49","author":"W-H Chou","year":"2003","unstructured":"Chou W-H, Yan F-X, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, de Leon J, Koch WH, Wedlund PJ (2003) Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49:542\u2013551. https:\/\/doi.org\/10.1373\/49.4.542","journal-title":"Clin Chem"},{"key":"3658_CR113","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/ijms24010526","volume":"24","author":"N Eissa","year":"2022","unstructured":"Eissa N, Awad MA, Thomas SD, Venkatachalam K, Jayaprakash P, Zhong S, Stark H, Sadek B (2022) Simultaneous antagonism at H3R\/D2R\/D3R reduces autism-like self-grooming and aggressive behaviors by mitigating MAPK activation in mice. Int J Mol Sci 24:526. https:\/\/doi.org\/10.3390\/ijms24010526","journal-title":"Int J Mol Sci"},{"key":"3658_CR114","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1038\/s41380-022-01509-7","volume":"27","author":"A Abrantes","year":"2022","unstructured":"Abrantes A, Giusti-Rodriguez P, Ancalade N, Sekle S, Basiri ML, Stuber GD, Sullivan PF, Hultman R (2022) Gene expression changes following chronic antipsychotic exposure in single cells from mouse striatum. Mol Psychiatry 27:2803\u20132812. https:\/\/doi.org\/10.1038\/s41380-022-01509-7","journal-title":"Mol Psychiatry"},{"key":"3658_CR115","doi-asserted-by":"publisher","first-page":"419","DOI":"10.31887\/DCNS.2014.16.3\/aguidotti","volume":"16","author":"A Guidotti","year":"2022","unstructured":"Guidotti A, Grayson DR (2022) DNA methylation and demethylation as targets for antipsychotic therapy. Dialogues Clin Neurosci 16:419\u2013429. https:\/\/doi.org\/10.31887\/DCNS.2014.16.3\/aguidotti","journal-title":"Dialogues Clin Neurosci"},{"key":"3658_CR116","doi-asserted-by":"publisher","first-page":"13768","DOI":"10.1038\/s41598-022-17503-6","volume":"12","author":"MDLA Robinson-Agramonte","year":"2022","unstructured":"Robinson-Agramonte MDLA, Michalski B, Vidal-Martinez B, Hern\u00e1ndez LR, Santiesteban MW, Fahnestock M (2022) BDNF, proBDNF and IGF-1 serum levels in na\u00efve and medicated subjects with autism. Sci Rep 12:13768. https:\/\/doi.org\/10.1038\/s41598-022-17503-6","journal-title":"Sci Rep"},{"key":"3658_CR117","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","volume":"89","author":"JJ Swen","year":"2011","unstructured":"Swen JJ, Nijenhuis M, de Boer A et al (2011) Pharmacogenetics: from bench to byte\u2014 an update of guidelines. Clin Pharmacol Ther 89:662\u2013673. https:\/\/doi.org\/10.1038\/clpt.2011.34","journal-title":"Clin Pharmacol Ther"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03658-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03658-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03658-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T07:04:28Z","timestamp":1715843068000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03658-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":117,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["3658"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03658-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki and approved by both the Institutional Review Board (IRB) committee of PNU (IRB Log Number: 20-0321) and KFMC (IRB Log Number: 20-758E).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from parents or other legal guardians of study participants after a clear rationalization of the study procedures was presented to them for review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}